• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

    6/20/24 7:30:00 AM ET
    $EMBC
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties
    Health Care
    Get the next $EMBC alert in real time by email

    WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. 

    (PRNewsfoto/Zimmer Biomet Holdings, Inc.)

    "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the Company's Board of Directors. "Dev brings a wealth of medtech, innovation and leadership experience that will be invaluable to ZB as we further advance our strategic priorities and mission to alleviate pain and improve peoples' lives."

    Mr. Kurdikar has served as the President and Chief Executive Officer and a member of the board of directors of embecta since its spinoff from BD on April 1, 2022.  He was the Worldwide President of Diabetes Care at BD from 2021 until the spinoff.  Prior to joining BD, Mr. Kurdikar was President and CEO of Cardiac Science Corporation (CSC) from 2016 to 2019.  Prior to that role, Mr. Kurdikar was the Vice President and General Manager, Men's Health, within Urology and Pelvic Health at Boston Scientific Corporation (Boston Scientific) from 2015 to 2016.  Mr. Kurdikar served in the same role at American Medical Systems (AMS) starting in 2013 and led the Men's Health business through its carve-out, sale and integration into Boston Scientific. Before joining AMS, Mr. Kurdikar worked for 11 years with Baxter International, Inc., holding leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations, ultimately serving as Vice President, Marketing, from 2011 through 2013.  He began his career as a Senior Research Engineer at The Monsanto Company.

    Mr. Kurdikar holds a Bachelor in Chemical Engineering from the University of Bombay (India). He earned a Master of Science in Chemical Engineering from Washington State University, a Ph.D. in Chemical Engineering from Purdue University, and a Master of Business Administration from Washington University.  In addition to serving on the embecta board, Mr. Kurdikar serves on the board of directors of AdvaMed (the Advanced Medical Technology Association).

    About Zimmer Biomet

    Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

    With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

    For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.twitter.com/zimmerbiomet.

    Cautionary Note Regarding Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this news release.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-announces-appointment-of-devdatt-kurdikar-to-board-of-directors-302177446.html

    SOURCE Zimmer Biomet Holdings, Inc.

    Get the next $EMBC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EMBC
    $ZBH

    CompanyDatePrice TargetRatingAnalyst
    Embecta Corp.
    $EMBC
    4/10/2025$15.00Neutral
    Mizuho
    Zimmer Biomet Holdings Inc.
    $ZBH
    12/17/2024$125.00 → $128.00Neutral → Overweight
    Analyst
    Embecta Corp.
    $EMBC
    12/2/2024$13.00 → $20.00Underweight → Equal-Weight
    Morgan Stanley
    Embecta Corp.
    $EMBC
    11/27/2024$26.00Neutral → Buy
    BTIG Research
    Zimmer Biomet Holdings Inc.
    $ZBH
    9/10/2024Peer Perform
    Wolfe Research
    Zimmer Biomet Holdings Inc.
    $ZBH
    7/1/2024$140.00 → $115.00Overweight → Neutral
    Piper Sandler
    Zimmer Biomet Holdings Inc.
    $ZBH
    5/30/2024$129.00Neutral
    Goldman
    Zimmer Biomet Holdings Inc.
    $ZBH
    5/21/2024$150.00Hold → Buy
    Argus
    More analyst ratings

    $EMBC
    $ZBH
    SEC Filings

    See more
    • SEC Form 10-Q filed by Embecta Corp.

      10-Q - Embecta Corp. (0001872789) (Filer)

      5/9/25 11:45:56 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Embecta Corp. (0001872789) (Filer)

      5/9/25 6:56:44 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zimmer Biomet Holdings Inc.

      SCHEDULE 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      5/6/25 4:46:12 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $EMBC
    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

      SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/14/24 1:22:34 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

      SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/13/24 1:44:56 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Embecta Corp.

      SC 13G/A - Embecta Corp. (0001872789) (Subject)

      11/8/24 10:57:43 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care

    $EMBC
    $ZBH
    Leadership Updates

    Live Leadership Updates

    See more

    $EMBC
    $ZBH
    Financials

    Live finance-specific insights

    See more
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

      WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

      3/6/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability

      5/9/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on

      5/9/25 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Zimmer Biomet Announces First Quarter 2025 Financial Results

      First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basisFirst quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposalsWARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025.  The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% ove

      5/5/25 6:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $EMBC
    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability

      5/9/25 6:30:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • embecta Announces Quarterly Cash Dividend

      PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on

      5/9/25 6:00:00 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Zimmer Biomet Announces First Quarter 2025 Financial Results

      First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basisFirst quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposalsWARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025.  The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% ove

      5/5/25 6:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $EMBC
    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $EMBC
    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $EMBC
    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SVP and CFO Elguicze Jacob covered exercise/tax liability with 4,948 shares, decreasing direct ownership by 3% to 168,599 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:25:00 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SVP, Global Manuf./Sup. Chain Curtis Shaun covered exercise/tax liability with 3,249 shares, decreasing direct ownership by 5% to 59,061 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:22:22 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • SVP, GC, Head Corp. Dev., Secy Mann Jeffrey Z covered exercise/tax liability with 5,285 shares, decreasing direct ownership by 4% to 139,439 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      4/8/25 4:20:11 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/25/25 4:26:16 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Melcher David F bought $32,500 worth of shares (2,000 units at $16.25), increasing direct ownership by 5% to 45,080 units (SEC Form 4)

      4 - Embecta Corp. (0001872789) (Issuer)

      2/12/24 7:08:59 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      11/13/23 4:02:02 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Mizuho initiated coverage on Embecta Corp. with a new price target

      Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00

      4/10/25 12:41:09 PM ET
      $EMBC
      Medical/Dental Instruments
      Health Care
    • Zimmer Biomet upgraded by Analyst with a new price target

      Analyst upgraded Zimmer Biomet from Neutral to Overweight and set a new price target of $128.00 from $125.00 previously

      12/17/24 8:26:36 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Embecta Corp. upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously

      12/2/24 6:56:10 AM ET
      $EMBC
      Medical/Dental Instruments
      Health Care